Vas Narasimhan

Vasant Narasimhan, physician-scientist and CEO who refocused Novartis into a pure-play medicines company, discusses platform bets in cell and gene therapy, RNA medicines, and radioligand therapies. He talks AI’s role across discovery and trials. He also covers global shifts in biotech, China’s rise, and what technical milestones and manufacturing work matter when partnering with startups.

Vas Narasimhan, the CEO of Novartis and a physician-scientist, discusses groundbreaking advancements in pharmaceuticals. He explores how AI is revolutionizing drug development and forming crucial partnerships with tech giants. Vas addresses Europe’s challenges in retaining competitiveness in the global market and emphasizes the need for coordinated reforms. He shares insights on the importance of leadership that prioritizes human connections and values resilience. His holistic approach to health and performance underscores the role of mindset and well-being in achieving innovation.

Vasant Narasimhan, CEO of Novartis and a physician-scientist, shares insights on pharmaceutical innovation and the role of AI in drug discovery. He discusses cutting-edge breakthroughs in cell therapies aimed at treating previously untreatable diseases. With a keen focus on Europe's pharmaceutical competitiveness, Vasant emphasizes the need for reform to enhance innovation. His leadership philosophy as a 'chief energy officer' intertwines health optimization and productivity, showcasing how personal well-being fuels corporate success.

Novartis CEO Vas Narasimhan discusses transforming the company into an innovative medicines giant. Topics include pharmaceutical innovations, AI in drug research, sustainability efforts, diversity & inclusion, and essential skills for CEOs. Insights on career growth in the pharmaceutical industry and market investment opportunities.

Vas Narasimhan, CEO of Novartis and a physician with a public‑health background, reflects on immigrant roots and a mission-driven career. He recounts choosing medicine and business to scale impact. He discusses tough leadership choices, owning failures, the emotional payoff of drug breakthroughs, and routines that sustain performance.